MUMBAI, India and NAPLES, Fla., April 7, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that ...
MUMBAI, India and NAPLES, Fla., April 10, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the ...
Zydus has received final approval from the USFDA to market Dapagliflozin Tablets in the strengths of 5 mg and 10 mg USRLD Farxiga Dapagliflozin is used with a proper diet and exercise program to ...
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (FDA) for dapagliflozin tablets, 5 mg and 10 mg (USRLD: Farxiga tablets, 5 mg and 10 mg).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results